Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Mexiko.
10. September 2021 06:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Mexiko. Infant Bacterial Therapeutics AB (IBT) meddelar idag att Patentverket i Mexiko beslutat utfärda ett...
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico
10. September 2021 06:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico Infant Bacterial Therapeutics AB today announces that the Mexican Patent Office has granted a patent entitled: A...
Rekryteringen av de minsta barnen i the Connection study pausad
25. August 2021 06:50 ET
|
Infant Bacterial Therapeutics AB
IBT påbörjade rekrytering av spädbarn till Strata A (vikt 500g-749g) i The Connection Study den 29 april 2021. Idag har 68 spädbarn rekryterats till gruppen. I enlighet med studieprotokollet och...
Recruitment of the smallest infants in the Connection study paused
25. August 2021 06:50 ET
|
Infant Bacterial Therapeutics AB
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport, 1 januari – 30 juni 2021
13. August 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför IBT en stor fas III-studie (“The Connection Study”) vilket är den sista studien i vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414, som...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2021
13. August 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development program with our drug candidate IBP-9414,...
Infant Bacterial Therapeutics AB utser Marie-Louise Alamaa till ny CFO
13. Juli 2021 11:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) tillkännagav idag att Marie-Louise Alamaa har utsetts till Chief Financial Officer (CFO) från och med den 16 augusti 2021. Hon kommer att ingå i företagets...
Infant Bacterial Therapeutics AB appoints Marie-Louise Alamaa as new CFO
13. Juli 2021 11:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August 16, 2021. She will be part of the Management...
Infant Bacterial Therapeutics CFO lämnar bolaget
20. Mai 2021 10:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs Chief Financial Officer (CFO) Daniel Mackey har bestämt sig för att lämna IBT för att anta nya utmaningar. Han kommer att fortsätta i sin nuvarande roll under...
Infant Bacterial Therapeutics CFO leaves the company
20. Mai 2021 10:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting...